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ABSTRACT The acetylcholine receptor from Torpedo cali-
fornica was labeled by reaction with the fluorescent probe 4-[N-
(iodoacetoxy)ethyl-N-methyl]amino-7-nitrobenz-2-oxa-1,3-diazole
without apparent effect on its in vitro ligand binding and functional
properties. Addition of acetylcholine or carbamoylcholine to the
labeled-receptor preparations enhanced the fluorescence of the
bound probe, and this effect was specific for agonists and inhibited
by prior incubation with excess a-bungarotoxin. Equilibrium flu-
orescence titrations gave apparent dissociation constants of 0.86
± 0.14 mM for carbamoylcholine and 79 ± 11 ,uM for acetylcho-
line, in good agreement with the dissociation constants measured
for the permeability response of the receptor. Stopped-flow ex-
periments showed that the fluorescence change was a single ex-
ponential process whose rate increased with ligand concentration,
reaching a saturating value for carbamoylcholine ofapproximately
400 s'-. The equilibrium binding of carbamoylcholine was not sig-
nificantly affected by prior incubation of the receptor with d-tubo-
curarine or histrionicotoxin and the dissociation constant was only
slightly increased in the presence of lidocaine. These inhibitory
ligands do not, therefore, compete directly with agonists for this
low-affinity binding site, suggesting that their mode of action may
be indirect.
The Torpedo acetylcholine (AcCho) receptor (AcChoR) has
been shown to undergo a time-dependent increase in agonist
affinity on exposure to these ligands and this has been correlated
with in vivo desensitization (1-6). This transition occurs on a
relatively slow time scale (tl2 80 s; ref. 6), and therefore rapid
kinetic techniques are necessary to monitor ligand-induced con-
formational changes occurring prior to receptor inactivation.
Recently, a variety of stopped-flow techniques have been used
to monitor the interaction ofagonists and the membrane-bound
AcChoR (7-16). Complex ligand binding kinetics were found
in each study, and these have been interpreted in terms of a
variety of mechanisms with, as yet, no agreement as to a com-
mon model. In all cases, conformational changes of the recep-
tor-ligand complexes were observed but the rate constants of
these processes appear too slow to account for channel opening.
Agonist-mediated 'Na' flux using AcChoR-enriched mem-
brane vesicles has been extensively studied by slow filtration
assays but the limited time resolution of these methods allows
only integrated responses to be measured and gives no infor-
mation on the rate of ion transport. Recently, techniques have
-been developed to monitor cation flux on more rapid time
scales. These involve quench-flow methods for monitoring
'Rb+ (17) or 22Na' efflux (18) and a rapid spectroscopic stopped-
flow technique based on Tl quenching of the fluorescence of
a fluorophore loaded within the vesicles (19). In these studies,
the apparent Kd values measured for carbamoylcholine
(CarbCho)-induced ion flux were in good agreement and ranged
from 0.5 to 6 mM, depending on the model used to fit the data.
These values are consistent with those measured in electro-
physiological studies (20, 21) but they are, however, inconsis-
tent with those obtained for CarbCho binding to the resting
state (30 ,M) or to the high-affinity desensitized state (0.1 AM)
in vitro (4, 6). Complicated kinetic models involving sequential
ligand binding steps have been proposed to account for this
discrepancy (17, 18).
In this communication, we describe the modification of the
membrane-bound AcChoR by reaction with the fluorescent
probe 4-[N-(iodoacetoxy)ethyl-N-methyl]amino-7-nitrobenz-2-
oxa-1,3-diazole (IANBD). Fluorescence changes of the bound
fluorophore were used to monitor the equilibrium and kinetic
properties of agonist binding and the results provide evidence
for the existence of a low-affinity binding site for agonists.
MATERIALS AND METHODS
AcChoR-enriched membrane fragments were prepared as de-
scribed (22, 23) with the exception that iodoacetamide was
excluded from the initial homogenization. Unless otherwise
stated, the buffer used in the final stages of preparation and the
experiments was 10 mM Hepes/35 mM NaNO3, pH 7.4.
Labeling of the membrane-bound receptor by IANBD (Mo-
lecular Probes) was achieved by first treating the membranes
[10 A.M in a-bungarotoxin (a-BTX) sites] with 50 p.M dithio-
threitol for 20 min at room temperature in Hepes buffer flushed
with argon. IANBD was added as a finely ground powder to give
a nominal concentration of 300 ,uM. The reaction mixture was
shielded from light and stirred for 2 hr at 4°C. Residual solid
IANBD and unreacted reagent were separated by passing the
mixture through a Sephadex G-25-300 column (1.7 X 24 cm)
and collecting the membrane fragments that eluted in the void
volume.
Fluorescence spectra were recorded on a Perkin-Elmer
MPF-4 spectrofluorimeter thermostatted at 25 ± 1°C. Equi-
librium dissociation constants were obtained from fluorescence
titration experiments using excitation and emission wavelengths
of482 and 540 nm, respectively. Small volumes ofconcentrated
ligand solution were added to 2 ml of AcChoR (1 to 2 AM in a-
BTX sites) and the fluorescence level was recorded immediately
after ligand addition. The data were corrected for nonspecific
effects from the results of a parallel titration of membrane frag-
ments previously incubated with excess a-BTX. Prior to titra-
tion with AcCho, acetylcholinesterase activity was measured
using acetylthiocholine as substrate (24) and only those prepa-
Abbreviations: AcCho, acetylcholine; AcChoR, acetylcholine receptor;
a-BTX, a-bungarotoxin; CarbCho, carbamoylcholine; HTX, histrioni-
cotoxin; IANBD, 4-[N-(iodoacetoxy)ethyl-N-methyl]amino-7-nitro-
benz-2-oxa-1,3-diazole; NBD, 4-[N-(acetoxy)ethyl-N-methyl]amino-7-
nitrobenz-2-oxa-1,3-diazole.
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rations that were devoid of esterase activity were used.
Kinetic data were obtained by using the stopped-flow in-
strumentation and data collection systems described in refs. 16
and 25.
At high ligand concentrations, the rate of the signal change
was so fast that a significant fraction ofthe process was complete
within the instrument dead time (approximately 2 ms). To re-
duce the inevitable artifacts introduced by this effect into the
rate constants derived from the data-fitting procedures, it was
occasionally necessary to fix the value of Al, the signal ampli-
tude (as defined in ref. 16), during the fitting procedure using
the observed amplitude at saturating concentrations of ligand.
The kinetics of agonist-mediated cation flux for control and
4-[N-(acetoxy)ethyl-N-methyl]amino-7-nitrobenz-2- oxa-1,3-di-
azole (NBD)-labeled membrane preparations were measured
by loading the vesicles with the fluorescent probe 8-amino-
naphthalene-1,3,6-trisulfonic acid (Chemical Services) and
monitoring the kinetics of TlV translocation by the stopped-flow
method described in ref. 19.
RESULTS
Spectral Properties of the NBD-Labeled AcChoR. After re-
duction of the AcChoR-enriched membrane fragments by low
concentrations of dithiothreitol, reaction with the sulfydryl-se-
lective alkylating reagent IANBD gave a highly fluorescent re-
ceptor preparation having broad fluorescence maxima for ex-
citation at 480 nm and emission at 535 nm, which are char-
acteristic of the properties of the bound fluorophore NBD (26,
27). Addition of CarbCho or AcCho led to a fluorescence en-
hancement that was saturable at high ligand concentrations.
This was completely abolished by prior incubation of the re-
ceptor with a-BTX, showing that it was specific for the AcChoR.
Preliminary studies of NBD labeling of the membrane-bound
receptor showed that specific fluorescence labeling could be
achieved even in the absence of dithiothreitol reduction. The
results, however, were variable and reproducibility was achieved
by introducing the reduction step.
Effect of NBD Labeling on the Properties of the AcChoR.
A major problem with the use of fluorescent probes to monitor
the ligand binding properties ofthe AcChoR is that introduction
of the probe may lead to perturbation of function. The ability
of the NBD-labeled preparation to mediate cation flux was
therefore studied by a quantitative rapid kinetic assay (19). Rep-
resentative Tl+ flux traces obtained for control and labeled
AcChoR preparations using a CarbCho concentration of0.1 mM
are shown in Fig. 1. The labeling procedures apparently did not
affect the cation flux properties of the receptor and the labeled
preparation displayed the expected pharmacological response
in that the agonist-induced enhancement of the rate of Tl1
transport was completely blocked by prior incubation of the re-
ceptor preparation with histrionicotoxin (HTX) (Fig. 1B). NBD
labeling also did not affect either the dissociation constants for
[3H]HTX or [3H]CarbCho binding or the number of high-af-
finity binding sites for these ligands. All these results indicate
that the labeled preparations retain their characteristic ligand
binding and functional properties.
Equilibrium Binding of Agonists to the NBD-Labeled
AcChoR. After alkali extraction and NBD-labeling of the re-
ceptor-enriched membrane fragments, the preparations were
frequently found to be devoid of acetylcholinesterase activity.
Equilibrium fluorescence titrations with AcCho could therefore
be carried out in the absence ofadded esterase inhibitors, which
interfered with the binding of or the fluorescence changes in-
duced by agonists (or both).
Addition ofAcCho led to a concentration-dependent increase
in fluorescence that could be fitted with precision by a simple
FIG. 1. Kinetics of CarbCho-induced Tl+ flux of control (A) and
NBD-labeled AcChoR (B). 8-Aminonaphthalene-1,3,6-trisulfonic acid-
loadedvesicles were mixed with 100 ,uM CarbCho and 17mM Tl (final
concentrations after mixing). The best-fit kinetic parameters were:
control, ki = 15.7 sl and Al = 412 mV; NBD labeled, k, = 22.0 s'1
andAl = 420 mV. The upper trace inB was recorded after mixing 100
pM CarbCho with NRD-labeled AcChoR previously incubated with 10
pM HTX.
binding process characterized by an apparent Kd of 88 ± 2 ,4M(Fig. 2A). The Hill coefficient, n, calculated from these data
(28) was 0.95 ± 0.11, emphasizing noncooperative ligand bind-
ing and clear deviation from the cooperative two-ligand binding
mechanism that is frequently invoked to describe the dose de-
pendency of conductance changes measured in electrophysio-
logical experiments (see ref. 29) (Fig. 2A).
Similar simple binding curves were obtained using CarbCho
as ligand and the results in Fig. 2B show that the apparent Kd
for CarbCho is about 0.96 mM (n = 0.99). The Kd values mea-
sured by equilibrium titration ofNBD-labeled preparations are
in good agreement with the effective dissociation constants
measured by Tl+ flux experiments (refs. 19, 30; unpublished
work) and these values compared in Table 1.
Effects of HTX, d-Tubocurarine, and Lidocaine. The li-
gand-induced enhancement of the fluorescence of the NBD-
labeled AcChoR was agonist specific since the fluorescence
level was unaltered by HTX, by the antagonist d-tubocurarine,
and by lidocaine, a local anesthetic, even when these ligands
were added in concentrations considerably in excess of their
known affinities for the receptor. Prior incubation of the
AcChoR with an excess of any of these ligands also had no dra-
matic effect on the binding of CarbCho, either with respect to
the measured Kd (Table 2) or the magnitude of the observed
fluorescence enhancement. Only lidocaine was found to cause
a slight (approximately 2-fold) increase in Kd; this effect is shown
in Fig. 2B.
Kinetics ofAgonist Binding to NBD-Labeled AcChoR. When
either CarbCho or AcCho was rapidly mixed with the NBD-la-
beled AcChoR, the resultant signal change appeared to be a
single exponential process and was completely blocked by prior
incubation with excess a-BTX, as shown for the binding of 1 mM
AcCho in Fig. 3. Both the rate and amplitude of the CarbCho-
induced signal change increased with the concentration of ag-
onist and showed saturation. The concentration dependence of
the amplitude paralleled the changes measured in equilibrium
titrations, and the data could be fit by a simple binding process
with a Kd of 0.73 mM (Fig. 4A). The rate also increased hy-
perbolically with CarbCho concentration and had limiting val-
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Table 2. Effects of previous incubation of NBD-labeled
membrane fragments with cholinergic ligands on
apparent Kd for CarbCho binding
Ligand Kd, mM
None 0.80 ± 0.19
d-Tubocurarine (10 gM) 0.85 ± 0.20
HTX (12.5 ILM) 0.98 ± 0.04
Lidocaine (20 mM) 2.2 ± 0.4
1.5
0 4 8 12 16 20
CarbCho, mM
FIG. 2. Fluorescence titration of NBD-labeled AcChoR by ago-
nists. (A) AcCho. , Best-fit line to the simple binding isotherm F1
= FO[L]/(Kd + [LI), whereF1 andF0 are the observed and equilibrium
fluorescence levels; Fo = 74.0 ± 0.4 and Kd = 88 + 2 ,M. ---, Fit to
the two-ligand binding mechanism F1 = F0/(1 + Kd/L)2 with F0 =
63.9 ± 0.3 and Kd = 23 + 1 ,uM. (B) CarbCho. , Curve calculated
by assuming F1 = Fo[L]/(Kd + [LI) and using the best-fit parameters
F0 = 103.8 ± 0.9 andKd = 0.96 + 0.02 mM. ---, Fluorescence titration
after incubation of AcChoRwith 20mM lidocaine. Best-fit parameters
were F0 = 102.7 + 1.8 and Kd = 1.78 ± 0.04 mM.
ues at zero and high concentrations of 83 s-1 (extrapolated) and
317 s-1, respectively (Fig. 4B).
DISCUSSION
One conceptual problem in the study of the AcChoR has been
the frequent lack of agreement between the apparent dissocia-
tion constants describing agonist-mediated permeability re-
sponses and those measured in direct ligand binding experi-
Table 1. Comparison of apparent Kd values for agonist binding
obtained by fluorescence titration and by cation
flux experiments
Apparent Kd
Binding to NBD-
Ligand labeled AcChoR Tl+ influx Ref.
AcCho 79.2 11.4 AM 44 AM* 30
140 ,uM Unpublished
CarbCho 0.86 0.14 mM 5 mM 19
1 mM* 19
0.5 mM* 30
* Data were fit by a model that assumed that binding of two ligand
molecules was required for channel activation [kapp = kmA/(l +
Kd/L)2].
ments. This has led to proposals ofcomplex kinetic mechanisms
involving sequential ligand binding steps and many different
receptor conformations having different affinities for agonists
(17, 18). The results presented here for the binding ofCarbCho
and AcCho to NBD-labeled preparations from Torpedo elec-
troplax suggest the existence of a low-affinity binding site for
agonists for which the measured equilibrium constants are in
agreement with the dependence on the concentration ofagonist
measured in rapid in vitro ion flux experiments using Torpedo
(refs. 18, 19, and 30; unpublished work) or Electrophorus (17)
AcChoR and in electrophysiological studies using the frog neu-
romuscular junction (20, 21).
These results appear to contradict the demonstration that,
in intact BC3H-1 cells, good correlation exists between an ag-
onist-induced affinity change of the AcChoR and both the ac-
tivation and desensitization responses (31, 32). For this species,
the results reported suggest that occupation ofone binding site
by agonist leads to both functional responses.
Affinity labeling techniques have previously shown that an
agonist binding site is located on the receptor subunit of Mr
-40,000 (33-37) and it is generally assumed that binding of
agonist to this site leads to channel activation. However, the
recent finding that all four subunits (Mr 40,000, 50,000, 60,000,
and 65,000) have extensive sequence homology (38) supports
the hypothesis that multiple binding sites of different affinities
and perhaps different functional properties may coexist. Such
a possibility is further supported by the observations that the
affinity label 4-azido-2-nitrobenzyltrimethylammonium fluo-
roborate (39) and the photoaffinity label (3-azidopyridinium)-
1, 10-diiododecane (40) labeled other receptor subunits in ad-
dition to that of Mr 40,000. It is not therefore unreasonable to
consider that functional properties of the AcChoR such as chan-
nel activation and desensitization may be the results of parallel
rather than sequential ligand binding pathways for the Torpedo
system.
The equilibrium fluorescence titration data show that the
binding ofAcCho or Carb has a simple hyperbolic dependence
on concentration and thus provide no evidence for multiple low-
affinity binding sites. Electrophysiological studies of the dose
dependence of conductance changes of Electrophorus elec-
FIG. 3. Kinetics of AcCho binding to NBD-labeled AcChoR. Mem-
brane fragments (1 to 2 ,uM in a-BTX sites) were mixed with 1 mM
AcCho before (upper trace) or after (lower trace) incubation with 3 ,uM
a-BTX for 30 min. , Curve calculated by using the best-fit param-
eters k, = 47.5 s-' and A1 = 302 mV.
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FIG. 4. Effect of CarbCho concentration on kinetics of binding to NBD-labeled AcChoR. Each point represents mean ± SD of at least four de-
terminations. (A) Effect of CarbCho concentration on the amplitude of the signal change. , Best-fit line to the equation F1 = Fo[L]/(Kd + [L]),
whereFo = 278.8 ± 0.5 (arbitrary units) andKd = 0.73 ± 0.01 mM. (B) Effect of CarbCho concentration on apparent rate constant. Data were fitted
to the mechanism shown in Eq. 1. , Curve calculated by using the parameters K1 = 12.6 ± 0.1 mM; k2 = 317 ± 1 s-1 and k.2 = 82.6 ± 0.5
-15 .
troplaque and muscle endplates have suggested that the chan-
nels usually open only when the receptor has two ligands bound
(21, 29, 41, 42). Although the fluorescence data do not conform
to the predictions ofa sequential cooperative two-ligand binding
mechanism, other more-complicated models involving two li-
gand-binding steps may be found to describe adequately the
observed behavior. Another possibility is that if, as is likely, the
observed signal change arises not from channel opening but
rather from a conformational change preceding activation, the
response itselfmay display cooperativity that is not necessarily
the consequence of cooperativity in ligand binding. In this re-
spect, it should'be noted that the observed low-affinity binding
also occurs under equilibrium conditions when, presumably,
the receptor is desensitized and thus channel opening is
unlikely.
The equilibrium binding of CarbCho to the low-affinity site
was unaffected by prior incubation of the receptor with either
the antagonist, d-tubocurarine, or HTX and was only slightly
perturbed by the presence of lidocaine. It has previously been
proposed that the blocking action by HTX (43, 44) and local
anesthetics (45) may be due to a direct block ofthe open channel
when the receptor is in its conducting state. The binding of ag-
onists to a receptor site responsible for activation may therefore
be insulated from such an action. d-Tubocurarine does not com-
pete for the low-affinity site for agonist because it neither itself
affected the fluorescence of NBD-labeled AcChoR nor inhib-
ited the binding of CarbCho, suggesting that the effect of an-
tagonists may be indirect, possibly due partially to a direct block
of the open channel as previously suggested (46).
Stopped-flow fluorescence experiments showed that the sig-
nal change accompanying the binding of CarbCho or AcCho to
the NBD-labeled AcChoR is an apparently first-order process
occurring on a rapid time scale. The concentration dependence
of the amplitude paralleled that measured in equilibrium titra-
tions, indicating not only that no unobservably fast process was
occurring but also that desensitization, which is unlikely to oc-
cur within the time of the kinetic experiments, does not affect
the equilibrium constant for binding to this site. The rate ofthe
signal change also had a hyperbolic dependence on ligand con-
centration and, thus, the process cannot be attributed to a bi-
molecular step but rather is likely -to reflect a conformational
change of the receptor-ligand complex. The nonlinear regres-
sion fitting of the data to a simple binding mechanism
K1 k2
R+L --RL=-I R*L, [1]
k-2
where kapp = k-2 + k2[L]/(K1 + [L]), is shown in Fig. 4B. It
should, however, be noted that this mechanism does not ade-
quately account for the data because the overall dissociation
constant obtained from the fit of the amplitude (0.73 mM) and
calculated.from the rate data (klk2 = 3.3 mM) are inconsistent.
Tlie true binding mechanism therefore must be more compli-
cated, but a simplistic representation of the conformational
change(s) may be considered [assuming that the isomerization(s)
and not the binding step(s) is rate limiting] as
/3
RL R*L,
a
[2]
where the fraction of R*L at equilibrium (y) is given by f3/(f3
+ a) which, for CarbCho is approximately 0.77. The rate con-
stants f3 and a for CarbCho as agonist are approximately 317 s5-1
and 83 sol, respectively, yielding an apparent rate constant of
about 400 s-1 at saturating ligand concentration (t1/2 = 1.7 ms).
This rate is considerably faster than the isomerization rate con-
stants previously measured in rapid kinetic experiments (7-15,
25) and is indeed in the range that might be expected for a rate-
limiting step in the process of activation of the population of
channels present in the membrane vesicle preparations.
The above simplified scheme has previously been invoked
to explain the results of electrophysiological experiments in
which a variety of techniques were used (29, 47, 48). In these
cases, R*L would denote the open channel form ofthe receptor
and y would be a measure ofthe efficacy ofan agonist to activate
the channel. Although this scheme empirically describes the
present fluorescence data, it is unlikely that R*L in this case
can be equated with the open channel state since the appear-
ance ofthis receptor conformation is unaffected by desensitization.
In summary, the results provide evidence for the, existence
of a low-affinity agonist binding site that is likely to be directly
involved in channel activation because (i) its affinity for agonists
is closely correlated with the apparent dissociation constants
measured for the permeability response and (ii) the rate con-
stants for ligand binding to the site are sufficiently high that they
are consistent with the rapidity of conductance changes mea-
sured in vivo. The low-affinity site exists under equilibrium
conditions and this suggests that desensitization and activation
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may be parallel processes and that the loss of response is not
due to perturbation of ligand binding to this site.
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